据吉利德科学消息6月30日lenacapavir(来那帕韦)作为HIV暴露前预防(PrEP)药物在海南博鳌乐城国际医疗旅

智通财经
Jun 30, 2025
据吉利德科学消息6月30日lenacapavir(来那帕韦)作为HIV暴露前预防(PrEP)药物在海南博鳌乐城国际医疗旅游先行区获批用于有感染HIV-1风险的成人和体重不小于35公斤的青少年进行暴露前预防以降低通过性行为感染HIV-1的风险。距离lenacapavir用于HIV预防在美国获批仅8个工作日这一创新药物就在博鳌乐城实现了“全球同步”准入。吉利德科学表示一年仅需给药两次的lenacapavir将有望进一步提升我国HIV防控格局的多元化进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10